Lensar (LNSR) Income from Continuing Operations (2019 - 2026)
Lensar (LNSR) posted quarterly Income from Continuing Operations of 42000.0 for Q1 2026, up 99.81% year-over-year from 21019.95 in Q1 2025, and up 99.19% quarter-over-quarter from 5158000.0 in Q4 2025.
Lensar (LNSR) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Lensar (LNSR) has reported Income from Continuing Operations for 8 consecutive years, with 42000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 99.81% year-over-year to 42000.0; the TTM figure through Mar 2026 stood at 46632000.0 (down 34.12% YoY), while the FY2025 annual figure was 36167000.0, down 106.41% from the prior year.
- Income from Continuing Operations grew to 42000.0 in Q1 2026 per LNSR's latest filing, from 5158000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 42000.0 in Q1 2026 and bottomed at 22122000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 8712647.06 across 5 years, with a median of 7259000.0 in 2023.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 539.88% — and 2026, when it jumped 99.81%.
- Lensar's Income from Continuing Operations stood at 2733000.0 in 2022, then decreased by 24.04% to 3390000.0 in 2023, then advanced by 13.13% to 2945000.0 in 2024, then tumbled by 75.14% to 5158000.0 in 2025, then jumped by 99.19% to 42000.0 in 2026.
- Business Quant data shows LNSR's Income from Continuing Operations at 42000.0 in Q1 2026, 5158000.0 in Q4 2025, and 20585000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Lensar | 102.19 Mn | 88.62 Mn | 9.78 Mn | 2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114,000.00 |
| Mar 31, 2026 | -42,000.00 |
| Dec 31, 2025 | -5.16 Mn |
| Sep 30, 2025 | -20.59 Mn |
| Jun 30, 2025 | -20.85 Mn |
| Mar 31, 2025 | -22.12 Mn |
| Dec 31, 2024 | -2.95 Mn |
| Sep 30, 2024 | -3.22 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | -7.27 Mn |
| Dec 31, 2023 | -3.39 Mn |
| Sep 30, 2023 | -7.26 Mn |
| Jun 30, 2023 | -4.08 Mn |
| Mar 31, 2023 | -9.54 Mn |
| Dec 31, 2022 | -2.73 Mn |
| Sep 30, 2022 | -10.27 Mn |
| Jun 30, 2022 | -11.14 Mn |
| Mar 31, 2022 | -11.03 Mn |
| Dec 31, 2021 | -4.43 Mn |
| Sep 30, 2021 | -11.57 Mn |